STALE?Report written 7 days ago · at $8.62entry levels may be stale — re-check before acting

CAPR

ค่าขนม

Capricor Therapeutics, Inc. · NASDAQ · Healthcare / Biotechnology (Cell Therapy)

$8.62

▼ 1.03%

MCap ~$497M (57.7M shares, Q1'26 count × $8.62)

⚠️ THESIS RECOVERY: the Aug 13 report ($4.19, written the day after a 9-3 negative adcomm vote) has more than doubled — +105.7% — to $8.62. This is not a random bounce: on Aug 24, 2026 the FDA extended the PDUFA from Aug 22 to Nov 22, 2026 after Capricor amended the BLA to claim only the upper-limb-function (PUL 2.0) endpoint — the narrower claim the adcomm gave directionally supportive feedback on even while voting against the broader cardiomyopathy indication.

BusinessCell therapy · Deramiocel for Duchenne muscular dystrophy — thesis materially RECOVERED (not broken) since the Aug 13 report: FDA extended the PDUFA to Nov 22, 2026 for a BLA narrowed to the upper-limb-function endpoint the adcomm was directionally supportive on

Thesis

⚠️ THESIS RECOVERED — this replaces the Aug 13 report, which correctly flagged the Jul 29-30 9-3 negative adcomm vote as breaking the original DMD-cardiomyopathy thesis and cut sizing to 1%. Since then, Capricor amended the BLA to claim ONLY the upper-limb-function endpoint (PUL 2.0) — the narrower claim the adcomm was directionally supportive on — and on Aug 24, 2026 the FDA granted a PDUFA extension to Nov 22, 2026 to review it. That is a real, positive regulatory signal: the FDA did not simply reject the amendment outright. The stock has re-rated from $4.19 to $8.62 (+105.7%) on this. But this is still Capricor's SECOND regulatory swing at the same drug after a Jul 2025 CRL and the Jul 2026 negative adcomm vote — not a clean bet. A shareholder letter (Kaos Capital, Aug 21) flagged cash burn ($237.9M as of Jun 30, 2026, down $80.2M from year-end 2025) and governance concerns, and active securities-fraud litigation continues. Consensus (8 analysts) $44.63 (Strong Buy) implies a huge headline upside, but that consensus predates the narrowed-indication amendment and should be treated with real skepticism until updated post-PDUFA.

📝 Primary Verdict · Core Holding

SPECULATIVEค่าขนม

SPECULATIVE — ค่าขนม-level sizing, not a core position. Measured median at-catalyst return across the core lane is -6.9% (n=54) — buying at today's $8.62 is not the default entry; the $6.80-7.40 dip is preferred. The thesis genuinely recovered (FDA extension + narrowed claim + directionally-supportive adcomm feedback on that specific endpoint is real, positive information), but this is still a second regulatory swing at a drug that already failed once — size for a binary outcome, not a sure thing.

85

score / 100 ⓘ

⚡ Catalyst

⚖️ Deramiocel PDUFA Decision — Upper-Limb Function Indication~8 WEEKS

FDA target action date for the amended BLA, narrowed to upper-limb function (PUL 2.0 primary endpoint) after the Jul 29-30, 2026 adcomm voted 9-3 against the original DMD-cardiomyopathy claim but gave directionally supportive feedback on this narrower endpoint. Extended from Aug 22 to Nov 22, 2026 on Aug 24, 2026.

Nov 22, 2026

📊 Q3 2026 Earnings~5 WEEKS

Cash-runway update ahead of the PDUFA. Company said in Aug 2026 it expects current resources to fund operations for at least 12 months, but a shareholder letter (Aug 21) flagged the pace of burn.

~Early Nov 2026

🎯 Entry Point

Entry 1

$8.62

Current price — already recovered +105.7% since the Aug 13 lowNow

Entry 2PREFERRED

$6.8–7.4

Pre-PDUFA dip zone / profit-taking retestIf dips

Entry 3

$4.50

Deep dip — near the post-adcomm-vote low ($4.19); only on a broad biotech selloff or fresh negative signalDeep dip only

✅ Take Profit

TP1

Base — FDA approves the narrowed upper-limb-only indication near the Nov 22, 2026 PDUFA; Base assumes the ~8-week catalyst-anchored horizon to the decision, well beyond the core lane's 14-day North Star window

$14.65

+70%

TP2

Bull — clean approval plus a stronger-than-expected initial launch reception, re-rating toward the low-to-middle of the (pre-amendment) analyst range

$20.69

+140%

TP3 🌙

Moon — approval plus early signals support could extend back toward the original cardiomyopathy indication · 2027

$30.17

+250%

🔴 Stop Loss

Tight Stop

fda_decision has n=3 in skill-feedback (context only, below the n≥5 floor) — using core.overall.medianMAE (-14%) as the reference; widened well beyond it given this is a name with one CRL and one negative adcomm vote already on record

$6.47

-25%

Hard Stop

Near the post-adcomm-vote low ($4.19) — a breach here means the market is pricing a second regulatory rejection

$4.74

-45%

Risk / Reward

Tight stop (-25%) vs TP2/Bull (+140%)

7.5 : 1

⚠ ⚠️ R/R is asymmetric on paper, but a CRL gaps through any stop overnight — this is not a name where the stop protects you cleanly

📅 Estimate Date

PDUFA Extension Granted (realized)

Extended from Aug 22 to Nov 22, 2026 after BLA amendment narrowed to upper-limb function

Aug 24, 2026

World Muscle Society Congress Data Presentation (realized)

24-month HOPE-3 + open-label extension data supporting the narrowed claim

Sep 17, 2026

PDUFA Decision

Approve vs CRL on the narrowed upper-limb-function claim

Nov 22, 2026

Genuinely uncertain — not a clean coin flip

Q3 2026 Earnings

Cash runway and litigation reserve are the numbers that matter most

~Early Nov 2026

n/a — pre-revenue

📈 Stock Timeline

3 snapshots · Jul 14 → Sep 29

Score

▲ 18

46

Jul 14Sep 29

TP2 Target

▲ 12

$20.69

Jul 14Sep 29

Rank

▼ 4

#20

Jul 14Sep 29

📈 Possible Up % — Scenario Spread

Bear

-50%

$4.31

Base

+70%

$14.65

Bull

+140%

$20.69

Moon

+250%

$30.17

← downsideupside →

🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

Fed hiked to 3.75-4.00% on Sep 16, 2026 (first hike since 2023); next FOMC Oct 27-28, 2026 — well before the Nov 22 PDUFA.

Inflation

Inflation-driven hike; CAPR's binary FDA-decision thesis is not meaningfully rate-sensitive either way, though a hawkish backdrop raises the cost of any post-PDUFA capital raise for commercial launch.

Sector Impact

Irrelevant to this name right now. A binary regulatory outcome, cash-burn pace, and litigation risk dominate anything rates do to a sub-$500M pre-revenue biotech.

Summary

LOW — macro is not the swing factor here; the Nov 22 PDUFA and the cash/litigation overhang are.

🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

H.C. Wainwright

Buy$60+596%

Cantor Fitzgerald

Overweight$62+619%

Wall Street Consensus (8 analysts)

Strong Buy$44.63+418%

current price $8.62

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

CAPR✅ GoodAug 2026

+106%

in 35 days

FDA extends PDUFA to Nov 22, 2026 after BLA amended to upper-limb-function-only claim

The event this refresh corrects for — a genuine, gradual recovery from the post-adcomm low, not a single-day pop. Same drug, same company, direct precedent for how the market re-prices a partially-derisked binary outcome.

CAPR❌ BadJul 2026

-36%

in 1 day

FDA advisory committee votes 9-3 against DMD-cardiomyopathy effectiveness

The event that originally broke the thesis. Direct precedent for the downside if the Nov 22 PDUFA disappoints again.

SRPT⚡ MixedJun 2023

-11%

in 1 day

Elevidys FDA accelerated approval (first DMD gene therapy) — restrictive label triggers a same-day drop despite the approval itself

A reminder that a narrow-label 'win' can still disappoint the market — CAPR's own narrowed upper-limb-only ask carries similar risk even in an approval scenario.

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-25% / -45%) only when trading the earnings spot — not for the core holding (use the -25% / -45% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

+105.7% cumulative (not a typical single pre-catalyst window — this is a post-setback recovery)Gradual, over the ~7 weeks since the Jul 30 adcomm low

CAPR has drifted UP steadily from $4.19 to $8.62 over the ~7 weeks since the adcomm low, as the market digested the PDUFA extension, the narrowed-claim rationale, and the Sep 17 WMS Congress data presentation — a genuine, gradual re-rate rather than a single pre-event pop

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +150%

range: +80% to +300%· Dec 2025

CAPR's own Dec 2025 Phase 3 HOPE-3 readout is the most direct precedent (+300% in 2 trading days on positive DMD data), but a November approval of an already-partly-priced-in narrowed claim would likely produce a smaller pop than a surprise data win. SRPT's narrow-label DMD approval (Jun 2023) is a cautionary comp — even an approval can disappoint if the label is restrictive.

❌ Catalyst Missavg -45%

range: -36% to -60%· Jul 30, 2026

CAPR's own Jul 30, 2026 reaction to the adcomm's 9-3 vote is the direct precedent (-36% in one day). A second rejection/CRL on the narrowed upper-limb indication in November would likely be at least as severe, possibly worse given it would be the drug's second regulatory setback on the same program.

💼Spot Position Sizing

How the recommended % is derived

2%

of portfolio

Raised from 1% in the Aug 13 report — the FDA extension and narrowed-claim path are genuine positive developments, not just a bounce — but kept well below the pre-adcomm 3% given this is still a second swing at a drug with one CRL and one negative adcomm vote on record

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-25%($6.47)

A break here before Nov 22 without news means the market is fading the extension's positive signal

After Catalyst (Bad Result)-45%

On a second CRL, exit into the first liquidity — a third regulatory attempt on the same drug is a multi-year proposition

📎 Sources

https://www.biospace.com/press-releases/capricor-therapeutics-announces-extension-of-pdufa-target-action-date-as-fda-continues-review-of-deramiocel-bla https://www.biospace.com/fda/fda-advisers-vote-against-approval-of-capricors-dmd-therapy-in-chaotic-adcomm-meeting https://www.globenewswire.com/news-release/2026/09/25/3369016/0/en/capr-stock-drop-alert-capricor-therapeutics-stock-plummets-64-after-clinical-data-issues-revealed-bfa-law-notifies-investors-of-the-imminent-september-28-deadline.html https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-capricor-stock-buy-rating-at-60-target-93CH-4814844 https://www.fiercebiotech.com/biotech/capricor-sets-2nd-approval-attempt-duchenne-cell-therapy-phase-3-win https://www.stocktitan.net/news/CAPR/https://stockanalysis.com/stocks/capr/statistics/

Generated 2026-09-29 · Not financial advice